Atropos Health and Kythera Labs Partner to Expand Access to Real-World Data to Advance Oncology
With the Kythera Labs collaboration, the Atropos Evidence Network continues to expand, adding the high-quality datasets needed to generate actionable insights. By utilizing Atropos Health's Real World Data Score® (RWDS) & Real World Fitness Score® (RWFS), users can select the dataset that is the most suitable to answer each question.
Kythera Labs' Oncology Event asset is a rich, high-fidelity dataset that provides comprehensive insights into the oncology care continuum, including patient interactions, treatment decisions, and provider engagements. Built from Kythera Labs' Remastered Source Data, the Oncology Event asset utilizes Kythera Labs' dynamic common data model and proprietary methodologies to ensure accuracy and depth. Through Atropos Evidence Network, organizations can quickly access actionable insights that support faster and more confident decisions in oncology research, clinical trials, and patient care.
'Growing the multimodal oncology network increases the opportunity for Atropos Evidence Network members to find more 'fit-for-purpose' data' said Dr. Brigham Hyde, CEO and co-founder of Atropos Health. 'Together with Kythera Labs, we will better enable healthcare organizations to accelerate and improve clinical decision making, clinical research productivity and clinical trial site selection and recruitment with novel evidence-based insights.'
The Atropos Evidence Network creates a market for data holders to expand the reach of these de-identified assets to a broader audience. Data contributors receive transparent, analytically driven feedback on usage and their own data quality and strengths. Atropos Health is the connection between real-world evidence (RWE) and actionable clinical analytics.
With the addition of Kythera Lab's purpose-built, remastered Real World Data, comprehensive, enriched insights into the full oncology care continuum, including patient interactions, provider engagements, and treatment nuances, will help spur innovation and optimize patient care strategies.
"At Kythera Labs, we are committed to closing the gaps between R&D and care delivery, moving insights from the clinical bedside to the research bench,' said Jeff McDonald, CEO and co-founder of Kythera Labs. 'Partnerships like this are integral to making progress within the field of oncology. By collaborating with Atropos Health and providing access to our enriched and analytics-ready data assets, we hope to help Evidence Network users reach answers faster and more cost-efficiently.'
The Atropos Evidence Network operates on GENEVA OS™ (Generative Evidence Acceleration Operating System), a federated model, forming secure, cloud-based connections between healthcare data proprietors and clinical insight seekers across the healthcare ecosystem. De-identified data doesn't change hands - institutional members of the network, such as a physician or researcher, can pose clinical questions to a variety of datasets. Within 48 hours, the user receives a novel retrospective observational study in response.
About Atropos Health
Atropos Health is the developer of GENEVA OS™ , the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence.
To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or follow on X (Twitter) @AtroposHealth.
About Kythera Labs
Kythera Labs is a data technology company that unifies data science and data technology to enable higher fidelity in healthcare data for Healthcare and Life Sciences organizations. Our multi-source data captures over 310M de-identified unique individuals and our technology is built for RWD users to integrate, access, analyze and find answers.
Learn more at www.kytheralabs.com or follow Kythera Labs on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Foresight Diagnostics Announces Publication of Landmark Study Demonstrating Prognostic Value of Ultrasensitive ctDNA-MRD Detection in Large B-Cell Lymphoma
BOULDER, Colo., Aug. 18, 2025 /PRNewswire/ -- Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection, today announced the publication of a landmark pooled analysis in the Journal of Clinical Oncology demonstrating that MRD analysis using Foresight CLARITY™ at end of therapy provided greater prognostic accuracy than PET/CT in large B-cell lymphoma (LBCL). The findings highlight the potential of ultrasensitive MRD testing as a robust and reliable tool for remission assessment following frontline treatment. The study integrated data from five prospective clinical studies and included 137 patients treated with curative-intent chemotherapy. MRD was measured using the Foresight CLARITY™ assay, which leverages PhasED-Seq™, a next-generation circulating-tumor DNA detection technology capable of identifying fewer than one mutant molecule per million.1 Key findings from the study include: ctDNA-MRD assessment was prognostic as early as after two cycles of frontline chemotherapy. Patients with undetectable MRD after 2 cycles achieved a 2-year progression-free survival (PFS) of 96% compared to 67% for patients with detectable MRD (hazard ratio 6.9; p=0.0025). ctDNA-MRD assessment was most prognostic at end of therapy: 78% of patients were MRD-negative and had a 2-year PFS of 97%, compared to just 29% among MRD-positive patients (hazard ratio 28.7; p<0.0001). By comparison, PET/CT status at end of therapy was less predictive, with a hazard ratio of 3.6. MRD status further stratified risk within both PET-negative and PET-positive groups at end of therapy. Patients with detectable MRD faced a higher risk of relapse even if their imaging was negative. Conversely, PET-positive patients with undetectable MRD had significantly better outcomes than patients with both positive imaging and MRD results. Overall, Foresight CLARITY™ demonstrated 86% clinical sensitivity for relapse detection and 91% clinical specificity for remission at end of therapy, based on a median follow-up of 37 months.2 "These findings highlight the clinical value of achieving ctDNA-MRD negativity at the end of treatment and underscore the limitations of relying solely on PET/CT for remission assessment," said Dr. David Kurtz, Chief Medical Officer at Foresight Diagnostics and co-author on the analysis. "With the ultra-high sensitivity of Foresight CLARITY™, we can detect disease that imaging misses, offering clinicians a more accurate and actionable tool for post-treatment risk stratification." "Our study illustrates the potential of ctDNA-MRD detection to more precisely define remission in B-cell lymphoma," said Dr. Mark Roschewski, Senior Clinician and Deputy Branch Chief of the Lymphoid Malignancies Branch at the Center for Cancer Research and lead author of the publication. "The results support the incorporation of novel surrogate endpoints such as molecular response into prospective studies evaluating how they could aid clinical decisions following frontline therapy." Ongoing trials are already evaluating ctDNA-guided treatment decisions in B-cell lymphoma. These include the ALPHA3 trial (NCT06500273), which is enrolling patients who achieve remission following frontline treatment but retain detectable ctDNA-MRD, and the SHORTEN-ctDNA study (NCT06693830), which is evaluating early ctDNA-MRD clearance as a potential marker to support frontline chemotherapy de-escalation. Additionally, the results from this pooled analysis were included in Foresight's clinical recommendations to the National Comprehensive Cancer Network® (NCCN®) and supported the December 2024 update to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas, which incorporated ctDNA-MRD testing as a tool to adjudicate PET-positive end-of-therapy scans.3 The full manuscript, titled "Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma," is available online in the Journal of Clinical Oncology. These findings were previously presented at the 2023 American Society of Hematology (ASH) Annual Meeting and the 2023 International Conference on Malignant Lymphoma (ICML). 1 Klimova, et al. Oncotarget 2025. 2 Sensitivity – of the 22 patients with disease progression, 19 were MRD positive at the end of treatment. Specificity – of the 101 patients that did not progress, 92 were MRD negative at the end of treatment. 3 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed 21 July 2025. To view the most recent and complete version of the guideline, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. About Foresight DiagnosticsForesight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. Its liquid biopsy platform, Foresight CLARITY™, is a novel assay that measures minimal residual disease (MRD) with reported detection limits in parts per million. The improved sensitivity of Foresight CLARITY™ has the potential to provide actionable information to physicians and biopharmaceutical companies to enable personalized treatment approaches for patients with solid tumor and hematologic malignancies. For more information, please visit and follow us on X, LinkedIn, and Bluesky. View original content to download multimedia: SOURCE Foresight Diagnostics, Inc.
Yahoo
2 hours ago
- Yahoo
Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?
Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics. The addition of Seagen in 2023 also strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. The acquired Seagen products contributed meaningfully to Pfizer's revenues in 2024 and in the first half of 2025. Seagen also has some next-generation ADC candidates in its pipeline. Oncology sales comprise more than 25% of Pfizer's total revenues. Its oncology revenues grew 9% in the first half of 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev, which made up for declining sales of drugs like Ibrance. Xtandi recorded alliance revenues of $566 million in the quarter, up 14% year over year. Lorbrena sales rose 48% to $251 million. Braftovi/Mektovi revenues were $182 million, up 23% year over year. New drug, Elrexfio, generated sales of $85 million in the second quarter. Ibrance revenues declined 8% year over year to $1.05 billion due to continued competitive pressure across markets. Among the ADCs added from the acquisition of Seagen, Adcetris sales were $255 million in the second quarter, which declined 9% year over year due to competitive pressure in the United States. Padcev rose 38% to $542 million, driven by strong demand trends. Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Revenues from oncology biosimilars were $353 million in the second quarter, up 27% year over year. Pfizer also advanced its oncology clinical pipeline with several candidates entering late-stage development, like sasanlimab, vepdegestrant and sigvotatug vedotin. By 2030, it expects to have eight or more blockbuster oncology medicines in its portfolio. In July, it closed a global ex-China in-licensing agreement with China's 3SBio for exclusive rights to the latter's dual PD-1 and VEGF inhibitor, which will strengthen its oncology pipeline. Pfizer is also working on expanding the labels of approved oncology drugs like Padcev, Adcetris and Elrexfio, among others. With all the above developments, Pfizer's future in cancer treatment looks promising. Continued growth of Pfizer's diversified portfolio of oncology drugs should support top-line growth in the second half of 2025. Competition in the Oncology Space Other large players in the oncology space are AstraZeneca AZN, Merck MRK and Bristol-Myers BMY. For AstraZeneca, oncology sales now comprise around 43% of total revenues. Sales in its oncology segment rose 16% in the first half of 2025. AstraZeneca's strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). Merck's key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. Keytruda's sales rose 6.6% to $15.1 billion in the first half of 2025. Bristol-Myers' key cancer drug is PD-L1 inhibitor, Opdivo, which accounts for around 20% of its total revenues. Opdivo's sales rose 9% to $4.82 billion in the first half of 2025. PFE's Price Performance, Valuation and Estimates Pfizer's stock has declined 0.4% so far this year compared with a decrease of 1.2% for the industry. Image Source: Zacks Investment Research From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company's shares currently trade at 8.08 forward earnings, lower than 14.45 for the industry and the stock's 5-year mean of 10.78. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has risen from $3.05 per share to $3.12 per share, while that for 2026 has gone up from $3.08 to $3.09 per share over the past 30 days. Image Source: Zacks Investment Research Pfizer has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution
SOUTH SAN FRANCISCO, Calif., August 19, 2025--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launched the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, a customizable, research-use-only solution designed to empower users to identify genomic alterations for a broad set of tumors, guide targeted therapy development and support clinical and translational oncology research. "We designed this panel to break the status quo in genomic profiling by offering laboratories a powerful alternative to locked, one-size-fits-all solutions," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "With our customizable content, flexible workflow, and compatibility with multiple sequencing platforms, Twist's Oncology DNA CGP Panel puts scientific control back in the hands of researchers and clinicians, particularly for those who need a more cost-effective solution compared to existing CGP products or a more efficient option than smaller panels." The Twist Oncology DNA CGP Panel was designed to serve a wide range of research groups including regional clinical labs, academic medical centers, and biopharma partners. The panel composition incorporates clinical research and includes a comprehensive and updated biomarker list covering 562 genes that incorporate all major tumor types. The panel's coverage spans genomic alterations and genomic signatures and can detect base substitutions, insertions and deletions (indels), copy number variations (CNVs), gene rearrangements as well as measure tumor mutational burden (TMB) and microsatellite instability (MSI). This is paired with Twist high quality and easy-to-use library preparation and target enrichment workflows. Twist is collaborating with several analytics companies to provide a complete solution from sequencing to analysis. About Twist Bioscience Corporation At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit Follow us on LinkedIn | X | YouTube | Instagram | Bluesky Twist Bioscience Legal Notice Regarding Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements about the expected future benefits and impact of the Twist Oncology DNA CGP Panel and collaborations with analytics companies. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; ability to obtain financing when necessary; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; and the ability to maintain and enforce intellectual property protection. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (SEC) on November 18, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. View source version on Contacts For Investors: Angela BittingSVP, Corporate Affairs925-202-6211abitting@ For Media: Amanda HoulihanCommunications Manager774-265-5334ahoulihan@
